Paul S. Gaynon, MD
Medical Director, Therapeutic Advances in Childhood Leukemia (TACL) consortium
Professor of Pediatrics, Keck School of Medicine, University of Southern California
Division of Hematology-Oncology, Children's Hospital Los Angeles
Dr. Paul Gaynon, Professor of Pediatrics at the University of Southern California, is a graduate of the Abraham Lincoln School of Medicine of the University of Illinois. He served his pediatric residency at Stanford University and his fellowship at Northwestern University. Dr. Gaynon introduced BFM-based ALL therapy in the United States in a Children’s Cancer Group (CCG) pilot study in 1981 and chaired two subsequent national CCG ALL trials. This BFM-based therapy serves as the platform for current COG studies in T-lineage and B-precursor ALL. Dr. Gaynon and Dr. Jim Nachman developed the “Augmented BFM” regimen, which has now become standard therapy in COG. Dr. Gaynon served as chair of the CCG ALL Strategy Group from 1993 until the merger with POG in 2000. He and Dr. Bruce Bostrom introduced dexamethasone in induction in the CCG-1922 study, which is now used in current COG standard risk therapy and in younger children with higher risk disease. Pegylated asparaginase was introduced in the CCG-1962 study. Dr. Gaynon served on the founding board of directors of the Madison, Wisconsin Ronald McDonald House. Drs. Gaynon, Nachman Pui, Schrappe, and Masera started the Ponte di Legno Working Group, which combines international data for small ALL subsets and has produced in several important publications. Dr. Gaynon served as medical director of the Therapeutic Advances in Childhood Leukemia (TACL) consortium, which now includes 40 member institutions in the United States, Canada, and Australia. He shares in authorship for over one hundred seventy publications. Dr. Gaynon is listed in Best Doctors in America.
Loading more stuff…
Hmm…it looks like things are taking a while to load. Try again?